Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 85, Issue 4, 2014, Pages 392-398

  Velasco, Roser ^a   Bruna, Jordi ^a   Briani, Chiara ^b   Argyriou, Andreas A ^c   Cavaletti, Guido ^d   Alberti, Paola ^d   Frigeni, Barbara ^e   Cacciavillani, Mario ^f   Lonardi, Sara ^g   Cortinovis, Diego ^e   Cazzaniga, Marina ^e   Santos, Cristina ^a   Kalofonos, Haralabos P ^c  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b UNIVERSITY OF PADOVA   (Italy)

^c UNIVERSITY HOSPITAL OF PATRAS   (Greece)

^d UNIVERSITY OF MILANO BICOCCA   (Italy)

^e SAN GERARDO HOSPITAL   (Italy)

^f CEMES   (Italy)

^g VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; DYSESTHESIA; DYSPHAGIA; DYSPNEA; EYE DISEASE; FASCICULATION; FEMALE; HUMAN; JAW DISEASE; LARYNX SPASM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCLE CRAMP; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NATIONAL COMMON INSTITUTE COMMON TOXICITY CRITERIA V.3; NERVE CONDUCTION; NERVE POTENTIAL; NEUROTOXICITY; PARESTHESIA; PERIPHERAL NEUROPATHY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PTOSIS; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SENSORY NERVE; SEX DIFFERENCE; SURAL NERVE; TOTAL NEUROPATHY SCORE; VOICE DISORDER;

EMG; NEUROONCOLOGY; NEUROPATHY; ONCOLOGY;

AGED; ANTINEOPLASTIC AGENTS; BIOMARKERS, PHARMACOLOGICAL; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEURAL CONDUCTION; ORGANOPLATINUM COMPOUNDS; PERIPHERAL NERVOUS SYSTEM DISEASES; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; SURAL NERVE; SYMPTOM ASSESSMENT;

EID: 84895820491     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2013-305334     Document Type: Article

References (40)

1. Rothenberg ML, Oza AM, Bigelow RH, et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 2003;21:2059-69. (Pubitemid 46606353)
2. Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343 -51.
3. Kalofonos HP, Aravantinos G, Kosmidis P, et al. Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study. Ann Oncol 2005;16:869-77. (Pubitemid 40903911)
4. Cassidy J, Clarke S, Díaz-Rubio E, et al. Randomized Phase III study of capecitabine plus oxaliplatin compared with fl uorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 2008;26:2006-12.
5. Cassidy J, Misset JL. Oxaliplatin-related side effects: characteristics and management. Semin Oncol 2002;29(5 Suppl 15):11-20. (Pubitemid 35191037)
6. Land SR, Kopec JA, Cecchini RS, et al. Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III Colon Cancer: NSABP C-07. J Clin Oncol 2007;25:2205-11. (Pubitemid 46954644)
7. Argyriou AA, Cavaletti G, Briani C, et al. Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancer. Cancer 2013;119:438-44.
8. Argyriou AA, Bruna J, Marmiroli P, et al. Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. Crit Rev Oncol Hematol 2012;82:51-77.
9. Kidwell KM, Yothers G, Ganz PA, et al. Long-term neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for colon cancer: results from National Surgical Adjuvant Breast and Bowel Project trials C-07 and LTS-01. Cancer 2012;118:5614-22.
10. Pietrangeli A, Leandri M, Terzoli E, et al. Persistence of high-dose oxaliplatin-induced neuropathy at long-term follow-up. Eur Neurol 2006;56:13- 16.
11. Cavaletti G, Cornblath DR, Merkies IS, et al. The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. Ann Oncol 2013;24:454-62.
12. Park SB, Lin CS, Krishnan AV, et al. Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility. Oncologist 2011;16:708-16.
13. Argyriou AA, Polychronopoulos P, Iconomou G, et al. A review on oxaliplatin-induced peripheral nerve damage. Cancer Treat Rev 2008;34:368-77.
14. Park SB, Lin CS, Krishnan AV, et al. Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. Brain 2009;132:2712-23.
15. National Cancer Institute: Common Terminology Criteria of Adverse Events Version 3.0. Available at: http://ctep.cancer.gov/reporting/ctc-v30.html (accessed 22 may 2011).
16. Cavaletti G, Frigeni B, Lanzani F, et al. The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale. J Peripher Nerv Syst 2007;12:210 -5.
17. Cornblath DR, Chaudhry V, Carter K, et al. Total neuropathy score: validation and reliability study. Neurology 1999;53:1660-4. (Pubitemid 29530336)
18. Frigeni B, Piatti M, Lanzani F, et al. Chemotherapy-induced peripheral neurotoxicity can be misdiagnosed by the National Cancer Institute Common Toxicity scale. J Peripher Nerv Syst 2011;16:228 -36.
19. Hughes R. NCI-CTC vs TNS: which tool is better for grading the severity of chemotherapy-induced peripheral neuropathy? Nat Clin Pract Neurol 2008;4:68-9. (Pubitemid 351248061)
20. Argyriou AA, Velasco R, Briani C, et al. Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients. Ann Oncol 2012;23:3116-22.
21. Kimura J. Electrodiagnosis in diseases of nerve and muscle, principles and practice. 3rd edn. Oxford: Oxford University Press, 2001;91-166.
22. Frigeni B, Cacciavillani M, Ermani M, et al. Neurophysiological examination of dorsal sural nerve. Muscle Nerve 2012;46:891 -4.
23. Grolleau F, Gamelin L, Boisdron-Celle M, et al. A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J Neurophysiol 2001;85:2293-7. (Pubitemid 32440704)
24. Cavaletti G, Tredici G, Petrucciolo MG, et al. Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat. Eur J Cancer 2001;37:2457-63. (Pubitemid 33097486)
25. Kanbayashi Y, Hosokawa T, Okamoto K, et al. Statistical identification of predictors for peripheral neuropathy associated with administration of bortezomib, taxanes, oxaliplatin or vincristine using ordered logistic regression analysis. Anticancer Drugs 2010;21:877-81.
26. Alejandro LM, Behrendt CE, Chen K, et al. Predicting acute and persistent neuropathy associated with oxaliplatin. Am J Clin Oncol Epub 2012 Apr 27.
27. Uwah AN, Ackler J, Leighton JC Jr, et al. The effect of diabetes on oxaliplatin-induced peripheral neuropathy. Clin Colorectal Cancer 2012;11:275-9.
28. Attal N, Bouhassira D, Gautron M, et al. Thermal hyperalgesia as a marker of oxaliplatin neurotoxicity: a prospective quanti fied sensory assessment study. Pain 2009;144:245-52.
29. Baek KK, Lee J, Park SH, et al. Oxaliplatin-induced chronic peripheral neurotoxicity: a prospective analysis in patients with colorectal cancer. Cancer Res Treat 2010;42:185-90.
30. Ramanathan RK, Rothenberg ML, de Gramont A, et al. Incidence and evolution of oxaliplatin-induced peripheral sensory neuropathy in diabetic patients with colorectal cancer: a pooled analysis of three phase III studies. Ann Oncol 2010;21:754 -8.
31. Goldberg RM, Tabah-Fisch I, Bleiberg H, et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 2006;24:4085 -91.
32. Argyriou AA, Polychronopoulos P, Koutras A, et al. Peripheral neuropathy induced by administration of cisplatin- and paclitaxel-based chemotherapy. Could it be predicted? Support Care Cancer 2005;13:647-51. (Pubitemid 41040187)
33. Cavaletti G, Bogliun G, Marzorati L, et al. Early predictors of peripheral neurotoxicity in cisplatin and paclitaxel combination chemotherapy. Ann Oncol 2004;15:1439-42. (Pubitemid 39295034)
34. Argyriou AA, Polychronopoulos P, Chroni E. The usefulness of nerve conduction studies in objectively assessing oxaliplatin-induced peripheral neuropathy. Oncologist 2007;12:1371-2. (Pubitemid 350232611)
35. Lehky TJ, Leonard GD, Wilson RH, et al. Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy. Muscle Nerve 2004;29:387-92. (Pubitemid 38269758)
36. Krishnan AV, Goldstein D, Friedlander M, et al. Oxaliplatin-induced neurotoxicity and the development of neuropathy. Muscle Nerve 2005;32:51-60. (Pubitemid 40917889)
37. Argyriou AA, Polychronopoulos P, Iconomou G, et al. Incidence and characteristics of peripheral neuropathy during oxaliplatin-based chemotherapy for metastatic colon cancer. Acta Oncol 2007;46:1131-7. (Pubitemid 350058888)
38. Burakgazi AZ, Messersmith W, Vaidya D, et al. Longitudinal assessment of oxaliplatin-induced neuropathy. Neurology 2011;77:980 -6.
39. Velasco R, Petit J, Clapés V, et al. Neurological monitoring reduces the incidence of bortezomib-induced peripheral neuropathy in multiple myeloma patients. J Peripher Nerv Syst 2010;15:17- 25.
40. Bruna J, Alé A, Velasco R, et al. Evaluation of pre-existing neuropathy and bortezomib retreatment as risk factors to develop severe neuropathy in a mouse model. J Peripher Nerv Syst 2011;16:199-212.